Centessa Pharmaceuticals plc
NASDAQ:CNTABiotechnology
-$0.07 today
- Market cap
- $6.27B
- Beta
- 1.12
- P/E (TTM)
- -24.4
- EPS (TTM)
- -$1.63
Volume 0.00M
Average 2.63M
CNTA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Centessa Pharmaceuticals plcNASDAQ: CNTA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$75.43M, compared with -$21.64M a year earlier. Trailing-twelve-month EBITDA was -$260.55M.
Context
- EBITDA amounted to 1222.2% of revenue in FY2025.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 12 analysts of $617.5K (+100.3%) for the fiscal year ending Dec 2026, a step up from the +17.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$75.43M+13.4% QoQ
- Last fiscal yearDec 2025
- -$183.33M+17.4% YoY
- LTMMar 2026
- -$260.55M-24.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -248.5% | +100.0% | +348.5 pp |
| 1 year | +17.4% | +100.3% | +83.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (183.33M) USD
- Year-over-year change
- +17.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (183.33M) | +17.4% |
| FY2024 | 2024-12-31 | (221.88M) | -34.1% |
| FY2023 | 2023-12-31 | (165.43M) | +21.1% |
| FY2022 | 2022-12-31 | (209.55M) | -50.4% |
| FY2021 | 2021-12-31 | (139.3M) | — |
EBITDA vs competitors
How CNTA compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -24.8% is the 6th highest of 10, against a peer median of -23.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $99.55M USD | +154.3% | — | 7.3% | |
| LTM Jun 2026 | -$168.8M USD | +13.6% | — | 37.5% | |
| LTM Jun 2026 | -$185.22M USD | -36.6% | — | — | |
| LTM Sep 2026 | -$233.76M USD | -54.9% | — | 3791.2% | |
| LTM Mar 2026 | -$260.55M USD | -24.8% | — | — | |
| LTM Jun 2026 | -$291.3M USD | -23.0% | — | — | |
| LTM Sep 2026 | -$434.65M USD | -30.9% | — | — | |
| LTM Jun 2026 | -$495.35M USD | -20.6% | — | — | |
| LTM Mar 2026 | -$503.35M USD | -11.9% | — | 75.2% | |
AAPGAscentage Pharma Group International | FY2025 | -CN¥1.1B CNY | -360.8% | — | 196.1% |
| Peer median (excluding CNTA) | — | -23.0% | — | 75.2% | |
Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 6.85M | 0 | 15M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 6.85M | 0 | 15M |
| Gross Margin | — | — | 100.0% | — | 100.0% |
| Research & Development | 96.32M | 155.08M | 124.41M | 150.24M | 172.22M |
| Selling, General & Admin | 43.01M | 55.2M | 53.73M | 50.81M | 50.47M |
| Operating Expenses | 374.87M | 212.26M | 178.14M | 201.06M | 222.69M |
| Depreciation & Amortization | 34K | 131K | 810K | 942K | 921K |
| EBITDA | (139.3M) | (209.55M) | (165.43M) | (221.88M) | (183.33M) |
| EBITDA Margin | — | — | -2413.9% | — | -1222.2% |
| Operating Income | (374.87M) | (212.26M) | (171.28M) | (201.06M) | (207.69M) |
| Operating Margin | — | — | -2499.4% | — | -1384.6% |
| Interest Income | 0 | 244K | 10.48M | 14.02M | 20.53M |
| Interest Expense | 2.55M | 7.28M | 9.91M | 10.09M | 11.46M |
| Other Income / Expenses | (6.92M) | (4.69M) | (4.86M) | (31.86M) | 11.98M |
| Income Before Tax | (381.79M) | (216.95M) | (176.14M) | (232.91M) | (195.71M) |
| Pre-Tax Margin | — | — | -2570.3% | — | -1304.8% |
| Income Tax Expense | 114K | (747K) | (25.06M) | 2.84M | 1.82M |
| Net Income | (381.9M) | (216.21M) | (151.09M) | (235.76M) | (197.53M) |
| Net Margin | — | — | -2204.7% | — | -1316.9% |
| EPS (Basic) | (4.24) | (2.31) | (1.57) | (2.06) | (1.46) |
| EPS (Diluted) | (4.24) | (2.31) | (1.57) | (2.06) | (1.46) |
| Weighted Avg Shares | 89.99M | 93.4M | 96.18M | 114.47M | 135.72M |
| Weighted Avg Shares (Diluted) | 89.99M | 93.4M | 96.18M | 114.47M | 135.72M |
Centessa Pharmaceuticals plc
NASDAQ:CNTA
Intrinsic Alpha fair value
Locked
Current Price
$40.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.